AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026. Management will participate in a fireside chat at 9:00 a.m. Central time.

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @AbbVie on LinkedIn, Facebook, Instagram, X and YouTube.

Media:

Catherine Langel   
(708) 508-3524
catherine.langel@abbvie.com

Investors:

Liz Shea
(847) 935-2211

liz.shea@abbvie.com

 

Cision View original content:https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-morgan-stanley-24th-annual-global-healthcare-conference-302868211.html

SOURCE AbbVie

News Provided by PR Newswire via QuoteMedia

AbbVieABBVnyse:abbvpharmaceutical investing
ABBV
The Conversation (0)
Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

- Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at week 14 versus placebo 1 - RINVOQ is the first and only Janus Kinase (JAK) inhibitor approved to... Keep Reading...
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

- Oral presentations highlight efficacy and safety outcomes from the upadacitinib (RINVOQ ® ) clinical trial program in adults with moderately to severely active Crohn's disease, and investigational use of linaclotide (LINZESS ® ) in treating functional constipation in pediatric patients aged 6... Keep Reading...
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin... Keep Reading...
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2026

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval. However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected... Keep Reading...
Marvel Announces Final Shank3 Data: MB-204 Highly Effective at Reversing Autism Behaviours

Marvel Announces Final Shank3 Data: MB-204 Highly Effective at Reversing Autism Behaviours

Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), a drug discovery company developing novel therapeutics for autism spectrum disorder ("ASD") and related neurodevelopmental disorders, is... Keep Reading...
Marvel Biosciences

Marvel Biosciences

Keep Reading...
Medical professional's hand under a digital interface with a glowing cross and circuit design.

Eli Lilly Brings AI to Drug Delivery in METiS TechBio Deal

METiS TechBio (HKEX:7666) could collect up to US$1.1 billion in milestone payments from Eli Lilly and Company (NYSE:LLY) under a new research pact to design lipid nanoparticles that carry medicines to specific tissues in the body.Lipid nanoparticles, or LNPs, carry therapeutic payloads to target... Keep Reading...
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. ("BriaPro"), today announced that four... Keep Reading...
Two people wearing lab coats shake hands in business agreement.

Telix Acquires Germany's ITM in US$1.65 Billion Deal

Melbourne-based Telix Pharmaceuticals (ASX:TLX) has agreed to acquire Germany’s ITM Isotope Technologies to secure commercial-scale radioisotope manufacturing and expand into neuroendocrine tumor treatments.The deal brings ITM’s global radioisotope production and distribution network spanning... Keep Reading...

Latest News

More News

Interactive Chart

Latest Press Releases

Brixton Metals Announces Closing of Final Tranche of Non-Brokered Private Placement

Canadian Investment Regulatory Organization Trade Resumption - TDG

One Bullion Advances Maitengwe Gold Project Toward Field Verification and Planned Drill Testing

Cerrado Gold Acquires the Past-Producing Manantial Espejo Mine in Santa Cruz, Argentina, from Pan American Silver

Related News

precious metals investing

Brixton Metals Announces Closing of Final Tranche of Non-Brokered Private Placement

precious metals investing

Canadian Investment Regulatory Organization Trade Resumption - TDG

precious metals investing

One Bullion Advances Maitengwe Gold Project Toward Field Verification and Planned Drill Testing

precious metals investing

Cerrado Gold Acquires the Past-Producing Manantial Espejo Mine in Santa Cruz, Argentina, from Pan American Silver

precious metals investing

Triumph Gold Announces Strategic Review of Non-Core Exploration Projects and $15 Million Private Placement

precious metals investing

Heliostar Presents Q3 2026 Financial and Operating Results with Record Mine Operating Earnings and Cash Balance

copper investing

Top 5 Australian Mining Stocks This Week: Raiden Resources Rises 33 Percent on Copper Deal